{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T16:49:16Z","timestamp":1749055756540,"version":"3.30.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00108-024-01812-1","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T18:26:30Z","timestamp":1731954390000},"page":"1216-1224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Was ist gesichert in der Therapie komplementvermittelter Nierenerkrankungen?","What is proven in the treatment of complement-mediated kidney diseases?"],"prefix":"10.1007","volume":"65","author":[{"given":"Jessica","family":"Kaufeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svjetlana","family":"Lovric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"issue":"11","key":"1812_CR1","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","volume":"8","author":"BP Dixon","year":"2023","unstructured":"Dixon\u00a0BP, Greenbaum\u00a0LA, Huang\u00a0L, Rajan\u00a0S, Ke\u00a0C, Zhang\u00a0Y, Li\u00a0L (2023) Clinical Safety and Efficacy of Pegcetacoplan in a\u00a0Phase\u00a02 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases. Kidney Int Rep 8(11):2284\u20132293. https:\/\/doi.org\/10.1016\/j.ekir.2023.08.033","journal-title":"Kidney Int Rep"},{"key":"1812_CR2","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1177\/0961203310371154","volume":"19","author":"DJ Birmingham","year":"2010","unstructured":"Birmingham\u00a0DJ et\u00a0al (2010) The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 19:1272\u20131280","journal-title":"Lupus"},{"issue":"8","key":"1812_CR3","doi-asserted-by":"publisher","first-page":"100855","DOI":"10.1016\/j.xkme.2024.100855","volume":"6","author":"BP Dixon","year":"2024","unstructured":"Dixon\u00a0BP, Kavanagh\u00a0D, Aris\u00a0ADM, Adams\u00a0B, Kang\u00a0HG, Wang\u00a0E, Garlo\u00a0K, Ogawa\u00a0M, Amancha\u00a0P, Chakravarty\u00a0S, Heyne\u00a0N, Kim\u00a0SH, Cataland\u00a0S, Yoon\u00a0SS, Miyakawa\u00a0Y, Luque\u00a0Y, Muff-Luett\u00a0M, Tanaka\u00a0K, Greenbaum\u00a0LA (2024) Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2\u2011Year Efficacy and Safety Outcomes in 2\u00a0Phase\u00a03. Trials kidney Med 6(8):100855. https:\/\/doi.org\/10.1016\/j.xkme.2024.100855","journal-title":"Trials kidney Med"},{"issue":"8","key":"1812_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","volume":"17","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri\u00a0F, Fr\u00e9meaux-Bacchi\u00a0V (2021) Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol 17(8):543\u2013553","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"1812_CR5","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1093\/ndt\/gfad140","volume":"38","author":"A Duval","year":"2023","unstructured":"Duval\u00a0A, Caillard\u00a0S, Fremeaux-Bacchi\u00a0V (2023) The complement system in IgAN: mechanistic context for therapeutic opportunities. Nephrol Dial Transplant 38(12):2685\u20132693. https:\/\/doi.org\/10.1093\/ndt\/gfad140","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1812_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s11825-018-0216-0","volume":"30","author":"W Feitz","year":"2018","unstructured":"Feitz\u00a0W, van de Kar\u00a0N, Orth-H\u00f6ller\u00a0D, van den Heuvel\u00a0L, Licht\u00a0C (2018) The genetics of atypical hemolytic uremic syndrome. medgen 30(4):400\u2013409","journal-title":"medgen"},{"key":"1812_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234934","author":"J Huang","year":"2020","unstructured":"Huang\u00a0J, Cui\u00a0Z, Gu\u00a0QH, Zhang\u00a0YM, Qu\u00a0Z, Wang\u00a0X, Wang\u00a0F, Cheng\u00a0XY, Meng\u00a0LQ, Liu\u00a0G, Zhao\u00a0MH (2020) Complement activation profile of patients with primary focal segmental glomerulosclerosis. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0234934","journal-title":"PLoS ONE"},{"issue":"4","key":"1812_CR8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1056\/NEJMx230010","volume":"390","author":"DRW Jayne","year":"2024","unstructured":"Jayne\u00a0DRW, Merkel\u00a0PA, Schall\u00a0TJ, Bekker\u00a0P, ADVOCATE Study Group. (2024) Avacopan for the Treatment of ANCA-Associated Vasculitis. N\u00a0Engl J Med 390(4):388\u2013325. https:\/\/doi.org\/10.1056\/NEJMx230010 (N Engl J Med. 2021;384(7):599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2023386)","journal-title":"N Engl J Med"},{"key":"1812_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/art.40747","volume":"71","author":"AHJ Kim","year":"2019","unstructured":"Kim\u00a0AHJ et\u00a0al (2019) Association of blood concentrations of complement split product iC3b and serum C3 with systemic lupus erythematosus disease activity. Arthritis Rheumatol 71:420\u2013430","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"1812_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","volume":"55","author":"K Kiryluk","year":"2023","unstructured":"Kiryluk\u00a0K, Sanchez-Rodriguez\u00a0E, Zhou\u00a0XJ et\u00a0al (2023) Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. nat Genet 55(7):1091\u20131105. https:\/\/doi.org\/10.1038\/s41588-023-01422-x","journal-title":"nat Genet"},{"issue":"6","key":"1812_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.semnephrol.2013.08.004","volume":"33","author":"H Ma","year":"2013","unstructured":"Ma\u00a0H, Sandor\u00a0DG, Beck\u00a0LH Jr. (2013) The role of complement in membranous nephropathy. Semin Nephrol 33(6):531\u2013542. https:\/\/doi.org\/10.1016\/j.semnephrol.2013.08.004","journal-title":"Semin Nephrol"},{"key":"1812_CR12","doi-asserted-by":"crossref","unstructured":"Perkovic V, Kollins D, Renfurm R et\u00a0al (2024) Efficacy and Safety of Iptacopan in Patients with IgA Nephropathy: Interim Results from the Phase\u00a03 APPLAUSE-IgAN Study. Present At World Congr Nephrol (WCN) 15: (Buenos Aires, Argentina)","DOI":"10.1093\/ndt\/gfae069.141"},{"issue":"12","key":"1812_CR13","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41581-023-00766-1","volume":"19","author":"V Petr","year":"2023","unstructured":"Petr\u00a0V, Thurman\u00a0JM (2023) The role of complement in kidney disease. Nat Rev Nephrol 19(12):771\u2013787. https:\/\/doi.org\/10.1038\/s41581-023-00766-1","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"1812_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/imr.12475","volume":"274","author":"CQ Schmidt","year":"2016","unstructured":"Schmidt\u00a0CQ, Lambris\u00a0JD, Ricklin\u00a0D (2016) Protection of host cells by complement regulators. Immunol Rev 274(1):152\u2013171. https:\/\/doi.org\/10.1111\/imr.12475","journal-title":"Immunol Rev"},{"issue":"13","key":"1812_CR15","doi-asserted-by":"publisher","first-page":"1009864","DOI":"10.3389\/fimmu.2022.1009864","volume":"24","author":"BYF So","year":"2022","unstructured":"So\u00a0BYF, Chan\u00a0GCW, Yap\u00a0DYH, Chan\u00a0TM (2022) The role of the complement system in primary membranous nephropathy: A\u00a0narrative review in the era of new therapeutic targets. Front Immunol 24(13):1009864\u2013PMC9639362. https:\/\/doi.org\/10.3389\/fimmu.2022.1009864","journal-title":"Front Immunol"},{"key":"1812_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ndt\/gfae069.434","volume":"39","author":"M\u00c1P Valdivia","year":"2024","unstructured":"Valdivia\u00a0M\u00c1P, Tumlin\u00a0JA, Kaufeld\u00a0J, Mai-Szu\u00a0W, Lafayette\u00a0R, Barratt\u00a0J, Susan Huang\u00a0S\u2011H, Fenoglio\u00a0R, Gyun Kim\u00a0S, Rice\u00a0K, Katefides\u00a0A, Garlo\u00a0K, Alamartine\u00a0E (2024) 145 Subgroup and secondary endpoint evaluation of a\u00a0phase\u00a02 randomized placebo-controlled trial of ravulizumab in IgA nephropathy. Nephrol Dial Transplant 39:1. https:\/\/doi.org\/10.1093\/ndt\/gfae069.434","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1812_CR17","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.kint.2019.04.028","volume":"96","author":"NA van de Lest","year":"2019","unstructured":"van de Lest\u00a0NA, Zandbergen\u00a0M, Wolterbeek\u00a0R et\u00a0al (2019) Glomerular C4d deposition can precede the development of focal segmental glomerulosclerosis. kidney Int 96(3):738\u2013749. https:\/\/doi.org\/10.1016\/j.kint.2019.04.028","journal-title":"kidney Int"},{"issue":"3","key":"1812_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","volume":"106","author":"M Vivarelli","year":"2024","unstructured":"Vivarelli\u00a0M, Barratt\u00a0J, Beck\u00a0LH Jr et\u00a0al (2024) The role of complement in kidney disease: conclusions from a\u00a0Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. kidney Int 106(3):369\u2013391. https:\/\/doi.org\/10.1016\/j.kint.2024.05.015","journal-title":"kidney Int"},{"key":"1812_CR19","doi-asserted-by":"publisher","first-page":"103216","DOI":"10.1016\/j.jaut.2024.103216","volume":"145","author":"K Watanabe-Kusunoki","year":"2024","unstructured":"Watanabe-Kusunoki\u00a0K, Anders\u00a0HJ (2024) Balancing efficacy and safety of complement inhibitors. J\u00a0Autoimmun 145:103216. https:\/\/doi.org\/10.1016\/j.jaut.2024.103216","journal-title":"J Autoimmun"},{"issue":"12","key":"1812_CR20","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","volume":"8","author":"E Wong","year":"2023","unstructured":"Wong\u00a0E, Nester\u00a0C, Cavero\u00a0T, Karras\u00a0A, Le Quintrec\u00a0M, Lightstone\u00a0L, Eisenberger\u00a0U, Soler\u00a0MJ, Kavanagh\u00a0D, Daina\u00a0E, Praga\u00a0M, Medjeral-Thomas\u00a0NR, G\u00e4ckler\u00a0A, Garcia-Carro\u00a0C, Biondani\u00a0A, Chaperon\u00a0F, Kulmatycki\u00a0K, Milojevic\u00a0J, Webb\u00a0NJA, Nidamarthy\u00a0PK, Junge\u00a0G, Remuzzi\u00a0G (2023) Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. Kidney Int 8(12):2754\u20132764. https:\/\/doi.org\/10.1016\/j.ekir.2023.09.017","journal-title":"Kidney Int"},{"issue":"1","key":"1812_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1600-065X.2008.00705.x","volume":"225","author":"PF Zipfel","year":"2009","unstructured":"Zipfel\u00a0PF, Skerka\u00a0C (2009) Complement factor\u00a0H and related proteins: an expanding family of complement-regulatory proteins? Immunol Rev 225(1):97\u2013112. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00705.x","journal-title":"Immunol Rev"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01812-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01812-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01812-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T22:03:24Z","timestamp":1733868204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01812-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1812"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01812-1","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"8 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Kaufeld erhielt Referenten\u2011\/Beraterhonorare von Alexion, AstraZeneca, Novartis und Sanofi. S.\u00a0Lovric erhielt Referenten\u2011\/Beraterhonorare von AstraZeneca und Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}